News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Alan Raffensperger Appointed Chief Operating Officer of Swedish Orphan Biovitrum


1/17/2012 8:54:02 AM

STOCKHOLM, SWEDEN--(Marketwire - January 17, 2012) -



Alan Raffensperger has been appointed Chief Operating Officer (COO) of Sobi with responsibility for Sales & Marketing, Supply Chain, Procurement and IT. His most recent position was CEO of Benechill Inc., an American medical device company within the hypothermia therapeutic field. During the years 2005 to 2010 he was employed by the American company Amgen and served as Executive Director, Head of Nephrology 2008-2010 based at the international headquarters in Switzerland, and General Manager of the Nordic and Baltic region 2005-2008, based in Sweden. Prior to that he was Sales and Marketing Director at Roche Pharmaceuticals, Sweden 1999-2004, Vice President, Global Marketing Diabetes Care at Roche Diagnostics 1996-1998 based in Germany, and Business Director Europe, Diabetes Care at Boeringher Mannheim 1994-1996, also based in Germany. He has also held leading positions within Pharmacia in Sweden and USA.

Alan Raffensperger, born in 1960, holds a Bachelor of Science from University of Maryland, Baltimore, USA. He will report to CEO Geoffrey McDonough and be a member of the Executive Leadership Team. The appointment takes effect immediately.

"We are delighted to welcome Alan to Sobi. The role of COO is part of the changes we are making to increase the effectiveness of our commercial operation. Alan brings an appropriate mix of operational and leadership experience in a variety of roles which will help to foster the evolution of Sobi in the years ahead," says Geoffrey McDonough, CEO of Sobi.

Swedish Orphan Biovitrum (Sobi)

Sobi is a leading integrated biopharmaceutical company dedicated to bringing innovative therapies and services to improve the health of rare disease patients and their families. The product portfolio comprises about 60 marketed products as well as projects in the late clinical phase. Key therapeutic areas are Inflammation and Genetics & Metabolism. In 2010 Sobi had revenues of SEK 1.9 billion and around 500 employees. The share (STO: SOBI) is listed on OMX NASDAQ Stockholm. More information is available atwww.sobi.com.

The information above has been published pursuant to the Swedish Securities Market Act and/or the Financial Instruments Trading Act. The information was released for public distribution on 17 January 2012 at 11:15 a.m. CET.

Please follow the link below for a picture of Alan Raffensperger.

http://www.sobi.com/Investors--Media/Imagebank/Senior-Management/

Sobi Press Release on January 17th in pdf format: http://hugin.info/134557/R/1578133/492245.pdf

This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that:

(i) the releases contained herein are protected by copyright and other applicable laws; and

(ii) they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Swedish Orphan Biovitrum AB (publ) via Thomson Reuters ONE

[HUG#1578133]


For further information, please contact:
Asa Stenqvist
Head of Communications and Investor Relations
Tel.: +46 8 697 21 88


Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES